BURLINGTON, Mass., Feb. 1 /PRNewswire-FirstCall/ -- Palomar Medical
Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of
light-based systems for cosmetic treatments, announced today that it will
unveil the new Palomar StarLux(R) 500 Laser and Pulsed Light System at the
65th Annual Meeting of the American Academy of Dermatology (AAD) in
Washington, D.C. from February 3rd to 5th. Palomar will also unveil five
new handpieces including the Lux1540-Z(TM) Fractional Laser Handpiece, the
LuxDeepIR(TM) Fractional Handpiece, and the LuxW(TM) and LuxYs(TM) Pulsed
Light Handpieces. Management will be available at the AAD for investor
demonstrations and to discuss Palomar's full line of products in booth
#1923 at the Washington Convention Center.
The new Palomar StarLux(R) 500 features 70% more power and increased
functionality and speed of treatment as compared to Palomar's successful
flagship product the StarLux(R) Laser and Pulsed Light System. Capable of
achieving higher peak and average power for greater efficacy with increased
contact cooling for added safety and comfort, the StarLux(R) 500 offers
customers faster treatment times, more flexibility, improved results, and a
faster return on their investment. The StarLux(R) 500 will support the same
suite of existing StarLux handpieces, as well as the newest offerings, two
of which can only be operated on the StarLux(R) 500 due to its higher power
capability.
The new Lux1540-Z(TM) Fractional Laser Handpiece offers fractional soft
tissue coagulation and non-ablative skin resurfacing (FDA cleared for soft
tissue coagulation. 510(k) submitted for skin resurfacing). Treatment
customization is provided by allowing the user to control micro-beam
density and focal depth as well as handpiece spot size (up to 15x15 mm).
The unique handpiece design allows easy visualization of the treatment
area.
The new LuxDeepIR(TM) Fractional Handpiece provides skin tightening
through soft tissue coagulation by more safely targeting deeper skin and
subcutaneous fat structures. This handpiece features advanced cooling for
superior comfort and safety, advanced contact sensors to insure proper
cooling, and a longer pulse duration for deeper penetration and higher
efficacy. With its fractional light delivery, advanced cooling, and long
pulse duration, the LuxDeepIR(TM) is able to penetrate deeper into the
dermis and fat layer while preserving the integrity of the epidermis and
upper dermis.
The new LuxW(TM) Pulsed Light Handpiece is optimized for treatment of
very light pigmented lesions, while the new LuxYs(TM) Pulsed Light
Handpiece provides permanent reduction of lighter, finer hair.
Chief Executive Officer Joseph P. Caruso commented, "Due to the
remarkable success achieved by the original StarLux(R) System, many of our
competitors are struggling to launch "me too" systems. With Palomar's
launch of the StarLux(R) 500, however, we again leap frog over our
competitors to offer a significantly advanced system with the further
benefit that it is built on the already proven and successful StarLux
platform. The StarLux(R) 500 will again raise the bar in our industry for
performance, capability, reliability, and safety. In addition, the launch
of four new handpieces, with more to come, demonstrates our commitment to
providing the most reliable, cost effective, expandable aesthetic system
available."
To reserve a time to meet with Palomar management and/or receive
product demonstrations, please contact Palomar's Investor Relations'
department at 781-993-2411 or ir@palomarmedical.com.
About Palomar Medical Technologies Inc: Palomar is a leading researcher
and developer of light-based systems for cosmetic treatments. Palomar
pioneered the optical hair removal field, when, in 1997, it introduced the
first high-powered laser hair removal system. Since then, many of the major
advances in light-based hair removal have been based on Palomar technology.
On December 8, 2006, Palomar became the first company to receive a 510(k)
over- the-counter (OTC) clearance from the United States Food and Drug
Administration (FDA) for a new, patented, home use, light-based hair
removal device. OTC clearance allows the product to be marketed and sold
directly to consumers without a prescription. There are now millions of
light-based cosmetic procedures performed around the world every year in
physician offices, clinics, spas and salons. Palomar is testing many new
and exciting applications to further advance the hair removal market and
other cosmetic applications. Palomar is uniquely focused on developing
proprietary light- based technology for introduction to the mass markets.
Palomar has an agreement with The Gillette Company to develop and
potentially commercialize a patented home-use, light-based hair removal
device for women. Palomar also has an agreement with Johnson & Johnson
Consumer Companies to develop and potentially commercialize home-use,
light-based devices for reducing or reshaping body fat including cellulite,
reducing the appearance of skin aging, and reducing or preventing acne.
For more information on Palomar and its products, visit Palomar's
website at http://www.palomarmedical.com. To continue receiving the most
up-to-date information and latest news on Palomar as it happens, sign up to
receive automatic e-mail alerts by going to the Investor Relations' section
of the website.
With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements,
including but not limited to statements relating to new markets, future
royalty amounts due from third parties, development and introduction of new
products, and financial and operating projections (including future tax
benefit from the Company's NOLs and future effective tax rates). These
forward-looking statements are neither promises nor guarantees, but involve
risk and uncertainties that may individually or mutually impact the matters
herein, and cause actual results, events and performance to differ
materially from such forward-looking statements. These risk factors
include, but are not limited to, results of future operations,
technological difficulties in developing or introducing new products, the
results of future research, lack of product demand and market acceptance
for current and future products, the effect of economic conditions,
challenges in managing joint ventures and research with third parties and
government contracts, the impact of competitive products and pricing,
governmental regulations with respect to medical devices, including whether
FDA clearance will be obtained for future products and additional
applications, the results of litigation, difficulties in collecting
royalties, potential infringement of third-party intellectual property
rights, factors affecting the Company's future income and resulting ability
to utilize its NOLs, and/or other factors, which are detailed from time to
time in the Company's SEC reports, including the report on Form 10-K for
the year ended December 31, 2005 and the Company's quarterly reports on
Form 10-Q. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. The
Company undertakes no obligation to release publicly the result of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
Contact: Kayla Castle
Investor Relations Manager
Palomar Medical Technologies Inc
781-993-2411
ir@palomarmedical.com
SOURCE Palomar Medical Technologies, Inc.
 back to top
Related links:
http://www.palomarmedical.com
http://www.aad.org/professionals/MeetingsEvents/2007AnnualMeeting.htm
http://www.prnewswire.com/comp/107555.html /
CONTACT:
Kayla Castle, Investor Relations Manager of
Palomar Medical Technologies Inc., +1-781-993-2411, or
ir@palomarmedical.com
|
